Senate Hearing on Sudden Price Spikes for Off-Patent Drugs
January 1, 2022
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing initiates a bipartisan investigation into drug pricing practices that directly impact costs for seniors and federal spending on programs like Medicare and Medicaid.
Potentially affected actors named in the source documents. Mention is not a position.
Seniors
Seniors rely on prescription drugs for health and face potential out-of-pocket cost increases.
Pharmaceutical Companies
These companies are the subject of the investigation regarding their pricing strategies for acquired off-patent drugs.
Federal Government
The government pays $110 billion annually for drugs through programs like Medicare and Medicaid, making it sensitive to price fluctuations.
Last recorded activity January 1, 2022.
Next step not available in the current record.
Summary
Key Facts
- The hearing marks the start of a bipartisan investigation into sudden price increases for off-patent prescription drugs.
- 90 percent of American seniors take at least one prescription drug per month.
- Total U.S. spending on prescription drugs is projected to exceed $328 billion in 2015.
- Individuals are expected to pay $50 billion out-of-pocket for prescription drugs in 2015.
- The Federal Government is expected to pay $110 billion for prescription drugs through Medicare, Medicaid, and Veterans' Affairs programs.
- Developing a new drug can take over a decade and cost between hundreds of millions to $5 billion.
- Only one in seven drugs that reach clinical trials receives FDA approval.
Frequently Asked Questions
What is an 'off-patent' drug?
Why is the Senate investigating these price spikes?
Why It Matters
This hearing initiates a bipartisan investigation into drug pricing practices that directly impact costs for seniors and federal spending on programs like Medicare and Medicaid.
News Coverage
Sponsors
Show 2 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Acquired Drugs
The committee is specifically targeting companies that acquire existing off-patent drugs to raise prices, rather than focusing solely on the cost of developing new drugs.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy60Intensity of disagreement among stakeholders
- Entertainment20Compellingness for a non-policy-wonk reader
- Buzz40Current news / social attention level
Publisher tools